Using tumor models to guide drug choice for advanced thyroid cancer
Treatments studied
Part of Cancer, Hormones & metabolism clinical trials.
This trial tests whether growing your tumor cells in a lab (as organoids) can help doctors pick the best drugs for advanced thyroid cancer that is hard to remove surgically. It's for people with different thyroid cancer types who have tumors growing outside the thyroid or into nearby areas.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a type of advanced thyroid cancer that has spread around the thyroid or come back after treatment.
- Your cancer is considered at risk of not being fully removable by surgery, based on tests like scans or throat exams.
- You have at least one tumor that can be measured on scans (by RECIST criteria).
- You are able to take care of yourself (ECOG score 0-2) and can swallow pills.
- Your major organs (bone marrow, liver, kidneys, heart) are working well enough at least 28 days before joining.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to choose chemotherapy for thyroid cancer by growing a 'mini-tumor' (organoid) from your biopsy and testing different drugs on it. The goal is to find the drug that is most likely to shrink your cancer.
This trial tests whether giving targeted drugs before surgery can help shrink advanced thyroid cancers, making them easier to remove. It uses your tumor's genetic profile to choose the best treatment for you.
This study looks at how different genetic types of advanced thyroid cancer respond to treatment in real-world settings. It may help doctors choose the best therapy for you based on your tumor’s genetic makeup.
This trial compares a targeted therapy pill combination (dabrafenib and trametinib) with cabozantinib or chemotherapy for people with a specific type of advanced thyroid cancer (differentiated thyroid cancer) that has a BRAF V600E mutation. It aims to find which treatment works better after previous treatments have stopped working.
This trial tests two targeted drugs, vemurafenib and cobimetinib, for people with high-risk thyroid cancer that has a specific BRAF V600E mutation. The goal is to see if this combination can help prevent the cancer from coming back after surgery or other initial treatments.
This study tests whether giving treatment before surgery (neoadjuvant therapy) helps people with locally advanced thyroid cancer. It aims to shrink the tumor so surgery can be more successful.
Hear when a new Locally Advanced Thyroid Gland Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.